Prieto-Pérez R - Search Results

1

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.

Prieto-Pérez R, Ochoa D, Cabaleiro T, Román M, Sánchez-Rojas SD, Talegón M, Abad-Santos F. Prieto-Pérez R, et al. J Clin Pharmacol. 2013 Dec;53(12):1261-7. doi: 10.1002/jcph.169. Epub 2013 Sep 17. J Clin Pharmacol. 2013. PMID: 23996211 Clinical Trial.

2

Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.

Cabaleiro T, Román M, Ochoa D, Talegón M, Prieto-Pérez R, Wojnicz A, López-Rodríguez R, Novalbos J, Abad-Santos F. Cabaleiro T, et al. Drug Metab Dispos. 2013 Jan;41(1):224-9. doi: 10.1124/dmd.112.046292. Epub 2012 Nov 1. Drug Metab Dispos. 2013. PMID: 23118328

3

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.

Román M, Ochoa D, Sánchez-Rojas SD, Talegón M, Prieto-Pérez R, Rivas Â, Abad-Santos F, Cabaleiro T. Román M, et al. Pharmacogenomics. 2014;15(15):1893-901. doi: 10.2217/pgs.14.141. Pharmacogenomics. 2014. PMID: 25495411

4

Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.

Ochoa D, Prieto-Pérez R, Román M, Talegón M, Rivas A, Galicia I, Abad-Santos F, Cabaleiro T. Ochoa D, et al. Pharmacogenomics. 2015;16(9):939-48. doi: 10.2217/pgs.15.40. Epub 2015 Jun 30. Pharmacogenomics. 2015. PMID: 26122864

5

Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.

Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F. Prieto-Pérez R, et al. Pharmacogenomics J. 2013 Aug;13(4):297-305. doi: 10.1038/tpj.2012.53. Epub 2013 Jan 22. Pharmacogenomics J. 2013. PMID: 23337970 Review.

6

New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study.

Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, Estebaranz JL, de la Cueva P, Daudén E, Abad-Santos F. Prieto-Pérez R, et al. Br J Dermatol. 2015;172(5):1432-5. doi: 10.1111/bjd.13585. Epub 2015 Mar 18. Br J Dermatol. 2015. PMID: 25639754 No abstract available.

7

Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.

Cabaleiro T, Prieto-Pérez R, Navarro R, Solano G, Román M, Ochoa D, Abad-Santos F, Daudén E. Cabaleiro T, et al. Pharmacogenomics J. 2016 Aug;16(4):336-40. doi: 10.1038/tpj.2015.53. Epub 2015 Jul 21. Pharmacogenomics J. 2016. PMID: 26194362

8

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.

Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, López-Estebaranz JL, de la Cueva P, Daudén E, Abad-Santos F. Prieto-Pérez R, et al. Pharmacogenomics J. 2018 Jan;18(1):70-75. doi: 10.1038/tpj.2016.64. Epub 2016 Sep 27. Pharmacogenomics J. 2018. PMID: 27670765 Free article.

9

[Application of pharmacogenomics and other new technologies to drug development].

Cabaleiro T, Prieto-Pérez R, Ochoa D, Abad-Santos F. Cabaleiro T, et al. Med Clin (Barc). 2013 Jun 18;140(12):558-63. doi: 10.1016/j.medcli.2013.02.010. Epub 2013 Apr 10. Med Clin (Barc). 2013. PMID: 23582104 Spanish. No abstract available.

10

Pharmacogenetics of topical and systemic treatment of psoriasis.

Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Román M, Abad-Santos F. Prieto-Pérez R, et al. Pharmacogenomics. 2013 Oct;14(13):1623-34. doi: 10.2217/pgs.13.163. Pharmacogenomics. 2013. PMID: 24088133 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters